Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS)

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. filer David Rodman plans to sell 14,058 shares of common stock through Merrill Lynch on 07/13/2026, using a broker assisted cashless exercise following the exercise of employee stock options. He also reported multiple sales of Mineralys common stock during the prior three months on various dates from April through July 2026.

Key Figures

Shares planned for sale: 14058 shares Aggregate market value of planned sale: 387716.51 Shares sold on 04/13/2026: 14058 shares +3 more

6 metrics

Shares planned for sale 14058 shares Common stock to be sold through Merrill Lynch on 07/13/2026

Aggregate market value of planned sale 387716.51 Market value of 14058 Mineralys common shares in proposed Form 144/A sale

Shares sold on 04/13/2026 14058 shares Common stock sold for an aggregate of 373086.81 during past 3 months

Shares sold on 05/13/2026 14056 shares Common stock sold for an aggregate of 401789.92 during past 3 months

Shares sold on 06/15/2026 9890 shares Common stock sold for an aggregate of 235487.24 during past 3 months

Shares sold on 07/09/2026 2171 shares Common stock sold for an aggregate of 65781.30 during past 3 months

Key Terms

Broker assisted cashless exercise, Exercise of employee stock options, Securities Sold During The Past 3 Months

3 terms

Broker assisted cashless exercise financial

"14058 | 07/13/2026 | Broker assisted cashless exercise"

Exercise of employee stock options financial

"07/13/2026 | Exercise of employee stock options | Mineralys"

Securities Sold During The Past 3 Months financial

"144/A: Securities Sold During The Past 3 Months"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 11:08 AM Accepted by SEC EDGAR 07/14/2026 - 11:08 AM Learn about SEC filing dates

FAQ

How many Mineralys Therapeutics (MLYS) shares is David Rodman planning to sell?

David Rodman plans to sell 14,058 shares of Mineralys Therapeutics, Inc. common stock. The planned sale is dated 07/13/2026 and will be executed through Merrill Lynch using a broker assisted cashless exercise after exercising employee stock options.

How will the planned Mineralys Therapeutics (MLYS) share sale be executed?

The planned transaction uses a broker assisted cashless exercise method. Shares are tied to the exercise of employee stock options and are scheduled to be sold on 07/13/2026 through Merrill Lynch, as disclosed in the Form 144/A securities information.

What prior Mineralys Therapeutics (MLYS) stock sales has David Rodman reported in the last three months?

David Rodman reported several sales of Mineralys common stock over three months, including 14,058 shares on 04/13/2026 for 373,086.81 and 14,056 shares on 05/13/2026 for 401,789.92, along with additional smaller trades on multiple April, May, June, and July 2026 dates.

On which exchange is Mineralys Therapeutics (MLYS) common stock listed in this disclosure?

The common stock referenced in this disclosure is listed on the NASDAQ. The securities information section identifies the security as Mineralys Therapeutics, Inc. common stock traded on NASDAQ in connection with the proposed Form 144/A sale.

Who is the broker for David Rodman’s planned Mineralys Therapeutics (MLYS) sale?

The proposed sale of 14,058 shares is to be executed through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281. The planned method is a broker assisted cashless exercise scheduled for 07/13/2026.

What is the aggregate market value of the Mineralys Therapeutics (MLYS) shares planned for sale?

The 14,058 Mineralys Therapeutics common shares planned for sale have an aggregate market value of 387,716.51. This figure appears in the securities information section alongside the share count, broker details, date of sale, and NASDAQ listing reference.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14058	387716.51	82498101	07/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/13/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			14058	07/13/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/13/2026	14058	373086.81
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/15/2026	6348	175585.68
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/17/2026	416	13033.28
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/11/2026	2171	64500.41
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/12/2026	6348	186348.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/13/2026	14056	401789.92
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	05/18/2026	417	11488.35
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/10/2026	2170	54250.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/12/2026	6349	151901.37
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/15/2026	9890	235487.24
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/17/2026	4584	114600.00
David Rodman 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	07/09/2026	2171	65781.30

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)